Key Points
- CEO Lawrence Otto Klein sold 75,000 Oruka Therapeutics shares at an average price of $91.83, generating approximately $6.89 million. The sale, executed under a pre-arranged Rule 10b5-1 plan, reduced his stake by 7.5% to 925,580 shares.
- Oruka shares opened at $92.11, with a market capitalization of roughly $6.1 billion, but the company reported a quarterly loss of $0.55 per share, missing analysts’ expectations of a $0.51 loss.
- Analyst sentiment remains broadly positive: 10 analysts rate the stock a Buy and one rates it a Sell, producing a consensus “Moderate Buy” rating and an average price target of $134.30.
Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) CEO Lawrence Otto Klein sold 75,000 shares of the company's stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $91.83, for a total value of $6,887,250.00. Following the sale, the chief executive officer owned 925,580 shares of the company's stock, valued at approximately $84,996,011.40. This trade represents a 7.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Lawrence Otto Klein also recently made the following trade(s):
- On Monday, June 15th, Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock. The shares were sold at an average price of $69.69, for a total value of $120,494.01.
Oruka Therapeutics Stock Performance
ORKA opened at $92.11 on Wednesday. The firm has a market cap of $6.10 billion, a P/E ratio of -45.37 and a beta of -0.34. The business has a 50 day moving average price of $94.92 and a 200 day moving average price of $68.59. Oruka Therapeutics, Inc. has a twelve month low of $14.66 and a twelve month high of $115.51.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.04). As a group, analysts anticipate that Oruka Therapeutics, Inc. will post -2.33 earnings per share for the current fiscal year.
Analysts Set New Price Targets
ORKA has been the topic of several research analyst reports. BTIG Research reaffirmed a "buy" rating and issued a $151.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Wall Street Zen cut Oruka Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, August 16th. Wedbush restated an "outperform" rating and set a $165.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. UBS Group lifted their price target on Oruka Therapeutics from $100.00 to $130.00 and gave the stock a "buy" rating in a research report on Wednesday, July 1st. Finally, HC Wainwright reiterated a "buy" rating and set a $120.00 price target on shares of Oruka Therapeutics in a report on Monday, August 3rd. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $134.30.
Get Our Latest Analysis on ORKA
Institutional Investors Weigh In On Oruka Therapeutics
Several hedge funds have recently made changes to their positions in the stock. Nykredit A S acquired a new stake in Oruka Therapeutics during the second quarter worth about $29,000. Orion Capital Management LLC bought a new stake in shares of Oruka Therapeutics in the 2nd quarter worth approximately $91,000. Royal Bank of Canada grew its holdings in shares of Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company's stock worth $34,000 after purchasing an additional 365 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of Oruka Therapeutics during the 4th quarter worth approximately $37,000. Finally, PNC Financial Services Group Inc. bought a new stake in shares of Oruka Therapeutics during the third quarter valued at approximately $39,000. Institutional investors own 56.44% of the company's stock.
About Oruka Therapeutics
(
Get Free Report)
Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”
The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
